跳至主要内容
临床试验/NCT00153790
NCT00153790已完成1 期

The Effect of Soy Lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and Green Tea-derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression

The Cooper Institute2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2005年4月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
60
试验地点
2
主要终点
Weight Loss

研究概览

简要总结

The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.

详细描述

Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
30 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen

排除标准

  • pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression

结局指标

主要结局

Weight Loss

Appetite Suppression

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验